5Mês·

BionTech - The biggest German stock market scandal since Wirecard

I think it's crazy that there's no news about it here yet, even though we have so many enthusiastic fans of $BNTX (+1,13%) among us. In my opinion, this topic should definitely be discussed a bit.


At the moment, BiontTech is planning to close virtually all its sites in Germany and lay off everyone who works there. More than 1900 employees are currently facing redundancy. That doesn't sound good, but it doesn't sound like a scandal either. Until you actually read the press releases to the end and find out what is really going on there.


What many people may not have realized is that BionTech took over its German competitor CureVac just a few months ago. Its production sites are even to be almost completely closed. Which of course raises a clear question: Why would you buy a company for money only to close it down?


The founder of CureVac, Ingmar Hoerr, provides an answer. He accuses BionTech of deception and explains that the takeover was probably mainly done to avoid legal disputes with CureVac and to secure patents. There was no interest at all in the actual company.


The chronology of events is also interesting. In January, the most important competitor was bought - which required the approval of the German authorities. In March, Ugur Sahin and his wife surprisingly leave their own company and want virtually nothing more to do with it. And in May, they suddenly come up with the idea of virtually winding up the entire shed by closing the central research and production sites.


Interesting ... interesting. And the state is snubbed on the one hand. About the fact that the company is publicly turning its back on the Federal Republic. About the fact that when the license for CureVac was granted, it was certainly not agreed that the competitor would only be bought in order to destroy it. About the fact that many well-paid jobs will be destroyed and millions in tax revenue will be lost. But on the other hand, the state is also up to its neck in the BionTech affair.


The BionTech Group is widely known. The company was founded by Ugur Sahin, his wife Özlem and a third guy who nobody is interested in because he has a German-speaking first name. Interestingly, the founding of the company by these three outstanding scientists was largely financed by taxpayers' money.


Then there was the well-known pandemic in which the state broke virtually all the rules to help BionTech. The company was granted special permits and emergency approvals even though the formal legal and scientific requirements were not, or at least not yet, in place. In addition, massive amounts of money were again spent to support BionTech financially.


There was also massive support from public media and institutes such as the RKI. Wikipedia still contains the information that the vaccine is 98% effective. Meanwhile, the RKI now only speaks of a "moderate protective effect" (quote from the website as at 10.12.2025) and links to studies by the ECDC that are less and less enthusiastic the more up-to-date the data becomes.


Yes, and here we are today. BionTech officially speaks of a "demand problem". That must be satire. Brother, your demand actually consisted of nothing other than "You inject yourself with this right now, otherwise you won't be allowed in the EDEKA".


And what's even worse is that BionTech can't really have any money problems. So they actually had a kind of infinite money cheat for a short time and instead of applying even a little bit of conservative German accounting, for years they have done nothing but buy pretty much every competitor in the biotechnology sector that can possibly exist in the world. I'm not kidding you when I say that they've even set up a site in Rwanda. However, they still don't have a single useful drug to show for it. True to the motto "If we can't get anything done, we can at least make sure that the others can't get anything done either"


For me, BionTech is and remains a red rag. A company whose business model is not vaccines, but bad sleight of hand. The decision to leave Germany cannot be due to the location. Nor can it be because of the money, because if I have seen correctly there is still 13 billion in cash in the account. From my point of view, it can only be due to the fact that they are strategically withdrawing before anyone gets the idea of launching a raid or a parliamentary committee of inquiry.


*(Private expression of opinion, no investment advice on this account)

attachment
50
42 Comentários

imagem de perfil
Reads like someone who has been consuming YouTube comments for months and now thinks they are an investigative journalist.
•
57
•
imagem de perfil
@trade_samuraia Do you have specific points that you are referring to / criticizing or are you just criticizing because the post feels bad in your stomach?
•
12
•
imagem de perfil
@trade_samuraia He has simply summarized the reports that have been written in the last few days from various media and added some personal opinions. What's wrong with that? Inform yourself and read the reports, form your own opinion and summarize it and then please let us know here
•
15
•
imagem de perfil
The fact that all locations in Germany are to be closed is simply wrong. 😉 In addition, the redundancies in Marburg are to take place without compulsory redundancies. You should stick to the truth.
•
2
•
imagem de perfil
@Aktienneuling-1979 Nowhere does it say that ALL locations will be closed. It says "virtually all" and later in the text I specify that this refers to the "central production and research locations" - in contrast to the office and administrative locations, which really don't interest anyone.

It's as if I say that the important mines in the Ruhr area have been shut down and you then say that's not true because there are still some that are used as museums today.
••
imagem de perfil
@Dividendenopi
The raid theory has zero evidence. Zero. That's not "mixing in opinion", that's selling speculation as a conclusion. And the vaccine coercion joke in the middle clearly shows where the journey is actually going.
•
10
•
imagem de perfil
@trade_samuraia
In addition, BioNTech has active oncology Phase 2 and Phase 3 trials ongoing "not a single useful drug" is simply wrong.
•
3
•
imagem de perfil
@trade_samuraia It's not a theory, but rather a suggestion. I mean that the supervisory authorities SHOULD take a look here, not that it will happen in reality. But you are welcome to explain objectively why it is legitimate and understandable to close state-of-the-art sites that have only recently been acquired.

And phase anything else = not a single useful drug. If you're a soccer club that hasn't signed any players, then there's no point in making a big deal about how you have the best youth department in the league and a world-renowned talent scout, but there's still no one on the pitch for you on Sunday
•
2
•
imagem de perfil
@trade_samuraia your comment reminds me of $NDX1...worked there myself...

...after the takeover of $ANA they always said no compulsory redundancies, the end of the story was exactly this reality. In addition, all locations were outsourced. The only thing that remained was the head office/administration in Hamburg and a small location ("research/development") in Rostock and why....

...so that it is still legitimized to tap into German tax money (subsidies) 🤫😉

Even central units of a wind turbine were manufactured in India, shipped to Germany, tested again here and that just to say "Made in Germany"

So keep your wits about you and inform yourself....

...it means something that the actual founders (2 of 3) no longer want to play the game for certain reasons and instead want to rebuild the original idea.

...picture doesn't really educate either 😘
•
1
•
imagem de perfil
@Soprano
Youth B is where the parents shout from the sidelines and the coach is called Bernd. Phase 2/3 shortly before approval is definitely not that. They cost billions and have real patients. And "suggestion" instead of "theory" doesn't change the fact that you have zero evidence. Speculation remains speculation no matter what you call it.
•
2
•
imagem de perfil
@trade_samuraia
You don't always buy a company because you want the locations. Sometimes you buy patents, IP, talents and the infrastructure is the accessory. This is normal M&A and not a scandal. A bit unpleasant for the employees, but "legitimate" is actually self-explanatory.
•
2
•
Ver todas as 22 restantes respostas
imagem de perfil
5Mês
Fact check: RKI says "moderate protective effect": From an asymptomatic or mild infection, right. But it doesn't really matter.
However, the vaccines offer good protection against severe illnesses. This lasts for about 6 months. The protection can be maintained or built up again with further booster vaccinations.

The available COVID-19 vaccines provide good protection against severe courses of the disease. The effectiveness of the vaccines is regularly tested.

Status: 10.12.2025 as claimed in the article. Source: https://www.rki.de/SharedDocs/FAQs/DE/Impfen/COVID-19/FAQ_Liste_Wirksamkeit.html#entry_16932152
•
14
•
imagem de perfil
@mco Correct. The "good protective effect" is backed up by linked studies, so everyone can look at the figures for themselves and decide whether they actually find them good and convincing.
••
@Multibagger What is your current opinion of $BNTX? You've been invested for a while and are convinced by their story, especially in the long term
•
2
•
imagem de perfil
@Migu11 I have already answered this question here with another user. I am still very convinced of the pipeline in the long term. In terms of image, the Curevac deal was certainly not so positive. That's why I sold everything beforehand in the short term (derivative and share). At the moment I simply see other positions in the biotech sector as more promising in the short term. First and foremost $CORT, which is currently my third-largest position in the portfolio after $PPTA and $IREN.
•
2
•
@Multibagger sorry, I missed that. But thank you anyway.
•
1
•
imagem de perfil
I used to work there (many years before Covid and so on). It was an interesting place before they started investing heavily.
•
2
•
imagem de perfil
My dear, somewhat exaggerated but still to the point. Unfortunately, there are many people who can't tell the difference between the message and the tone.

When the news broke, I already commented once that I couldn't understand the value of BionTech. Research gone, top staff gone, patents outsourced, licenses as revenue? CureVac ... let's not go there.

No idea what the investment case is, I'm already out of there, losses realized. Remaining funds invested in QQQ3 and very happy with it so far.
••
imagem de perfil
@DumpMoney Well, I don't think they like the tone or the message, because the topic itself is emotional for some. Many find it very difficult to question their opinion once they have decided on a team. No matter whether it's soccer, investment or anything else.

The share is only stable because they have a lot of cash. It's like a small piggy bank that can still be slaughtered, but not a promising biotech stock
••
imagem de perfil
Hugely BIASED shyt post 😄
••
Participar na conversa